Evolocumab safety and efficacy in hypercholesteremia patients with or without diabetes: a retrospective real-world analysis.

ABSTRACT:

Background

Proprotein convertase subtilisin/kexin type 9 inhibitors effectively reduce LDL cholesterol and adverse cardiovascular events with a safety profile comparable to a placebo. Limited real-world data exists on their effectiveness in different patient groups. This study evaluated evolocumab's efficacy and safety in hypercholesteremia patients with and without diabetes.

Method

In a large tertiary hospital in Saudi Arabia, patients aged 18 and above who initiated evolocumab therapy were screened for eligibility between January 2017 and July 2023. All patients who had been on maximally tolerated statin and ezetimibe therapy for at least 4 months before starting evolocumab were included. The included participants were then divided into diabetic and non-diabetic groups and

SUBMITTER: Alraddadi SI 

PROVIDER: S-EPMC11783923 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature